XYREM 500 MG
SODIUM OXYBATE : 500 MG · DIN 02268272 · JAZZ PHARMACEUTICALS IRELAND LIMITED
Health Canada status: MARKETED
What is XYREM?
XYREM 500 MG contains SODIUM OXYBATE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02268272, held by JAZZ PHARMACEUTICALS IRELAND LIMITED, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Jan-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XYREM used for?
XYREM (sodium oxybate) oral solution is indicated for treatment of cataplexy in patients with narcolepsy. XYREM is not recommended for use in other indications, as safety and efficacy have not been established outside of cataplexy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02268272 |
|---|---|
| Brand name | XYREM |
| Generic / active ingredient | SODIUM OXYBATE : 500 MG |
| Manufacturer | JAZZ PHARMACEUTICALS IRELAND LIMITED |
| Strength | 500 MG |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA I) |
| ATC code | N07XX04 HYDROXYBUTYRIC ACID |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Jan-2018 |
How is it stored and handled?
null
How is it supplied?
Each amber oval PET bottle contains 180 mL of XYREM oral solution at a concentration of 500 mg/mL and is sealed with a child-resistant cap.
What can be used instead?
Other Canadian products sharing ATC code N07XX04 HYDROXYBUTYRIC ACID. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| XYWAV | 0.096 G | SOLUTION | JAZZ PHARMACEUTICALS IRELAND LIMITED | MARKETED | DIN 02538237 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.